Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -41.18% is in line with its 5-year average of -40.22%, around the middle of its 5-year range (-86.55%–-4.08%).
31.63% above its 12-month average of -60.23%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -10.20%.
RETURN ON ASSETS (ROA)
-41.18%
RETURN ON ASSETS (ROA) AVG TTM
-60.23%
RETURN ON ASSETS (ROA) AVG 3Y
-53.11%
RETURN ON ASSETS (ROA) AVG 5Y
-40.22%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+31.63%
CURRENT VS 3Y AVG
+22.46%
CURRENT VS 5Y AVG
-2.40%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.27%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
-27.63%
vs the sector median at left
Pasithea Therapeutics Corp.
Market Cap
$14.94M
Return on Assets (ROA)
-41.18%
TTM Avg
-60.23%
3Y Avg
-53.11%
5Y Avg
-40.22%
Market Cap
$14.73M
Return on Assets (ROA)
-201.89%
TTM Avg
-113.65%
3Y Avg
-83.24%
5Y Avg
-72.72%
Market Cap
$15.30M
Return on Assets (ROA)
-213.77%
TTM Avg
-110.51%
3Y Avg
-93.41%
5Y Avg
-68.22%
Market Cap
$14.46M
Return on Assets (ROA)
-123.23%
TTM Avg
-153.35%
3Y Avg
-205.77%
5Y Avg
-166.29%
Market Cap
$15.58M
Return on Assets (ROA)
2.23%
TTM Avg
5.13%
3Y Avg
7.99%
5Y Avg
9.09%
Market Cap
$15.68M
Return on Assets (ROA)
-38.41%
TTM Avg
-84.87%
3Y Avg
-95.12%
5Y Avg
-75.66%
Market Cap
$15.78M
Return on Assets (ROA)
-154.34%
TTM Avg
-227.23%
3Y Avg
-240.86%
5Y Avg
-184.63%
Market Cap
$14.05M
Return on Assets (ROA)
-15.57%
TTM Avg
-20.73%
3Y Avg
-20.84%
5Y Avg
-41.87%
Market Cap
$13.86M
Return on Assets (ROA)
-172.58%
TTM Avg
-148.41%
3Y Avg
-106.72%
5Y Avg
-82.10%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Pasithea Therapeutics Corp. (KTTA) | $14.94M | -41.18% | -60.23% | -53.11% | -40.22% |
| Karyopharm Therapeutics Inc. (KPTI)vs › | $14.73M | -201.89% | -113.65% | -83.24% | -72.72% |
| Cocrystal Pharma, Inc. (COCP)vs › | $15.30M | -213.77% | -110.51% | -93.41% | -68.22% |
| Vyome Holdings, Inc. (HIND)vs › | $14.46M | -123.23% | -153.35% | -205.77% | -166.29% |
| Jin Medical International Ltd. (ZJYL)vs › | $15.58M | 2.23% | 5.13% | 7.99% | 9.09% |
| Allarity Therapeutics, Inc. (ALLR)vs › | $15.68M | -38.41% | -84.87% | -95.12% | -75.66% |
| BioCardia, Inc. (BCDA)vs › | $15.78M | -154.34% | -227.23% | -240.86% | -184.63% |
| Pulsenmore Ltd. Ordinary Shares (PLSM)vs › | $14.05M | -15.57% | -20.73% | -20.84% | -41.87% |
| Sintx Technologies, Inc. (SINT)vs › | $13.86M | -172.58% | -148.41% | -106.72% | -82.10% |
| Obsidian Therapeutics Inc. (OBX)vs › | $13.75M | N/A | N/A | N/A | N/A |
ROA
-41.2%
ROE
-42.7%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -33.91% |
| 2024-12-31 | -86.55% |
| 2023-12-31 | -61.12% |
| 2022-12-31 | -30.85% |
| 2021-12-31 | -4.08% |
| 2020-12-31 | -24.79% |
